FUNDAMENTALS · Fundamentals · TW Healthcare

Ever Supreme Bio Technology (6712) Fundamentals 2026 — P/E 28.3x, Revenue Analysis | SniperIQ

Ever Supreme Bio Technology (6712) is a TW-listed Healthcare company in Biotechnology with a market capitalization of NT

5.2B, trading at NT
49.00 on the TWO. This SniperIQ fundamentals page covers Ever Supreme Bio Technology's valuation (P/E 28.3x, P/B 5.0x), profitability (net margin 45.9%), revenue (NT
.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapNT
5.2B
P/E (TTM)28.3x
Net Margin45.9%
Revenue (FY25)NT
.0B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Ever Supreme Bio Technology's market cap?

Ever Supreme Bio Technology (6712) has a market capitalization of approximately NT

5.2B, trading at NT
49.00 on the TWO. Market cap moves with the live share price.

What is Ever Supreme Bio Technology's P/E ratio?

Ever Supreme Bio Technology's trailing twelve-month P/E ratio is 28.3x, with a price-to-book (P/B) of 5.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Ever Supreme Bio Technology?

Ever Supreme Bio Technology runs a net profit margin of 45.9%, a gross margin of 72.3%, and an operating margin of 44.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Ever Supreme Bio Technology generate?

Ever Supreme Bio Technology reported revenue of NT

.0B for fiscal year 2025, with net income of NT$429M and earnings per share (EPS) of 4.88. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Ever Supreme Bio Technology pay a dividend?

Ever Supreme Bio Technology offers a trailing dividend yield of about 2.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Ever Supreme Bio Technology financially healthy?

Ever Supreme Bio Technology carries a debt-to-equity ratio of 0.01x and a current ratio of 1.76x, with a market beta of 0.41. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Ever Supreme Bio Technology a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Ever Supreme Bio Technology (6712) the key facts are: market cap NT

5.2B, P/E 28.3x, revenue NT
.0B, 52-week range 120.95238-184. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Ever Supreme Bio Technology's full fundamentals live

Get Ever Supreme Bio Technology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Medpace Holdings (MEDP) fundamentals · Winning Health Technology Group (300253) fundamentals · Amrutanjan Health Care (AMRUTANJAN) fundamentals · Shanghai Haoyuan Chemexpress (688131) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons